

DT01 Rec'd PCT/PTC 20 DEC 2004

SEQUENCE LISTING

<110> Levinson, Arnold I.
Weiner, David B.
Otero, Miguel
Calarota, Sandra

<120> Vaccines for Suppressing IgE Mediated Allergic Disease and
Methods for Using the Same

<130> UPAP0024-500 (Penn 02725)

<160> 13

<170> PatentIn version 3.2

<210> 1
<211> 88
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 1
cccaagctta tggactggac ctggatcctc ttcttggtgg cagcagccac gcgagtccac 60
tcccatgggc tggctggcgg ctccgcgc 88

<210> 2
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 2
ccgctcgagc gtggggctgg aggacgttgg 30

<210> 3
<211> 87
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 3
ccgctcgaga gaaacgagct gtcgtaggat ccgatccaaa ttatttaagg actgattctg 60
ataaagatag atttttataa accatgg 87

<210> 4
<211> 88
<212> DNA
<213> Artificial Sequence

100	105	110	
gtg cag cgg ttc ctc tca gcc acg cgg cag ggg agg ccc cag acc tcc			384
Val Gln Arg Phe Leu Ser Ala Thr Arg Gln Gly Arg Pro Gln Thr Ser			
115	120	125	
ctc gac tac acc aac gtc ctc cag ccc cac gcc aga gaa aaa aga gct			432
Leu Asp Tyr Thr Asn Val Leu Gln Pro His Ala Arg Glu Lys Arg Ala			
130	135	140	
gtt gtt ggt tac gat cca aat tat tta agg act gat tct gat aaa gat			480
Val Val Gly Tyr Asp Pro Asn Tyr Leu Arg Thr Asp Ser Asp Lys Asp			
145	150	155	160
aga ttt tta caa acc atg gta aaa ctg ttt aac aga att aag aga gaa			528
Arg Phe Leu Gln Thr Met Val Lys Leu Phe Asn Arg Ile Lys Arg Glu			
165	170		175
aaa aga gct gtt gtt ggt ttt aat aat ttt acc gtt agc ttt tgg ttg			576
Lys Arg Ala Val Val Gly Phe Asn Asn Phe Thr Val Ser Phe Trp Leu			
180	185		190
agg gtt cct aaa gta tct gct agt cat tta gaa cat cat cat cat cat			624
Arg Val Pro Lys Val Ser Ala Ser His Leu Glu His His His His His			
195	200	205	
cat tag			630
His			

<210> 6
 <211> 209
 <212> PRT
 <213> Homo sapiens

<400> 6

Met Asp Trp Thr Trp Ile Leu Phe Leu Val Ala Ala Ala Thr Arg Val
 1 5 10 15

His Ser His Gly Leu Ala Gly Gly Ser Ala Gln Ser Gln Arg Ala Pro
 20 25 30

Asp Arg Val Leu Cys His Ser Gly Gln Gln Gln Gly Leu Pro Arg Ala
 35 40 45

Ala Gly Gly Ser Val Pro His Pro Arg Cys His Cys Gly Ala Gly Arg
 50 55 60

Ala Asp Trp Pro Gly Pro Pro Glu Leu Asp Val Cys Val Glu Glu Ala
 65 70 75 80

Glu Gly Glu Ala Pro Trp Thr Trp Thr Gly Leu Cys Ile Phe Ala Ala
 85 90 95

Ala Gly Gly Ser Val Pro His Pro Arg Cys His Cys Gly Ala Gly Arg
1 5 10 15

Ala Asp Trp Pro Gly Pro
20

<210> 9
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 9

Glu Leu Asp Val Cys Val Glu Glu Ala Glu Gly Glu Ala Pro Trp
1 5 10 15

<210> 10
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 10

Glu Ala Pro Trp Thr Trp Thr Gly Leu
1 5

<210> 11
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> peptide

<400> 11

Thr Gly Leu Cys Ile Phe Ala Ala Leu Phe
1 5 10

<210> 12
<211> 27
<212> PRT
<213> Artificial Sequence

<220>
<223> peptide

<400> 12